KROS
Keros Therapeutics, Inc.
Keros Therapeutics, Inc. (KROS) has 2 SEC Form 4 filings (2 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 6, 2026.
- Industry:Biotechnology
- CEO:Jasbir S. Seehra
- Employees:163
- HQ:Lexington, MA, US
- IPO:2020-04-08
Insider Buying
$10K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$218.3M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Purchase | 1,000 | $10K | Jun 17 | SEC ↗ |
Related companies
Keros Therapeutics, Inc. is in the Healthcare sector.